Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SHARON: Study of Metastatic Cancers in Patients Using Autologous Stems Cells and Potentiated Redox Cycling to Overcome Drug Resistance to Nitrogen Mustard Derivatives

NCT04150042 is registered in ClinicalTrials.gov with General Oncology, Inc. as lead sponsor.

NCT NCT04150042
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04150042 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SHARON: Study of Metastatic Cancers in Patients Using Autologous Stems Cells and Potentiated Redox Cycling to Overcome Drug Resistance to Nitrogen Mustard Derivatives
Lead sponsor
General Oncology, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
January 13, 2021
Completion date
December 31, 2028
Enrollment
24 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the breast, brca1 mutation, brca2 mutation, breast cancer metastatic, breast cancer stage iv, her2 negative breast carcinoma, her2-negative breast cancer, metastatic pancreatic cancer, metastatic pancreatic ductal adenocarcinoma, palb2 gene mutation, pancreas cancer, pancreas cancer, metastatic, pancreas cancer, recurrent, pancreatic acinar cell carcinoma, pancreatic adenocarcinoma metastatic, pancreatic cancer, pancreatic cancer stage iv, pancreatic ductal adenocarcinoma, stage 4 pancreatic cancer, stage iv pancreatic cancer